The effect of yoga therapy on angiotensin I and II, N-terminal pro-B-type natriuretic peptide, nitric oxide, and catecholamines in heart failure patients (NYHA I-II): A pilot study

Abstract

Background: Heart failure (HF) is a significant global health issue; the incidence and prevalence of HF are on the rise due to the aging population and the widespread presence of risk factors associated with HF. Research studies have demonstrated the efficacy of yoga therapy in enhancing patient outcomes among individuals diagnosed with HF. Nevertheless, there is a scarcity of research examining the impact of yoga on biomarkers associated with HF. Aims and Objectives: The primary objective of the present research is to investigate the viability and potential advantages of integrating yoga therapy as a component of the therapeutic approach for individuals diagnosed with HF. Materials and Methods: Eighty patients with New York Heart Association class I and II conditions were recruited and randomly divided into two groups. The control group (CG) was administered standard medical therapy, whereas the yoga group (YG) was given supplementary yoga therapy alongside the conventional medical treatment. Results: Angiotensin I reduced 32.17% in CG and 43.85% in YG, angiotensin II reduced 29.12% and 37.52%, N-terminal pro-B-type natriuretic peptide reduced 37.49% in CG, 48.88% in YG, nitric oxide increased 39.62% in CG, 59.86% in YG, and catecholamines decreased 39.2% (CG) and 49.86% (YG). The results of this study indicate that the practice of yoga therapy led to statistically significant improvements in several key biomarker. Conclusion: The integration of yoga into a comprehensive health-care protocol has the potential to yield favorable outcomes pertaining to the regulation of blood pressure, cardiovascular well-being, vascular functionality, as well as a decrease of stress levels among individuals with HF.